Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | C19H16ClF3N6O2 |
| Molecular Weight | 452.818 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
FC1=C(CNC(=O)CN2C(Cl)=CN=C(NCC(F)(F)C3=CC=CC=N3)C2=O)N=CC=C1
InChI
InChIKey=AATHXZYXWMKUFC-UHFFFAOYSA-N
InChI=1S/C19H16ClF3N6O2/c20-15-9-27-17(28-11-19(22,23)14-5-1-2-6-25-14)18(31)29(15)10-16(30)26-8-13-12(21)4-3-7-24-13/h1-7,9H,8,10-11H2,(H,26,30)(H,27,28)
| Molecular Formula | C19H16ClF3N6O2 |
| Molecular Weight | 452.818 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Approval Year
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 11:47:14 GMT 2023
by
admin
on
Sat Dec 16 11:47:14 GMT 2023
|
| Record UNII |
S6MPG81Y84
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Code | English | ||
|
Code | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DPOC-4088
Created by
admin on Sat Dec 16 11:47:14 GMT 2023 , Edited by admin on Sat Dec 16 11:47:14 GMT 2023
|
PRIMARY | CAS Number: 312904-62-4 | ||
|
S6MPG81Y84
Created by
admin on Sat Dec 16 11:47:14 GMT 2023 , Edited by admin on Sat Dec 16 11:47:14 GMT 2023
|
PRIMARY | |||
|
DPOC-4088
Created by
admin on Sat Dec 16 11:47:14 GMT 2023 , Edited by admin on Sat Dec 16 11:47:14 GMT 2023
|
PRIMARY | A study to investigate the concentrations of a new drug DPOC-4088 in blood, and to study the effect of this drug on blood clotting parameters. Furthermore the relation between the blood concentrations and the blood clotting effect will be investigated. Safety will be investigated as well. The objective of these investigations is to determine the optimal dose of DPOC-4088 that, achieves a relevant increase in a specific blood clotting parameter (the ecarin clotting time) without safety concerns. | ||
|
312904-62-4
Created by
admin on Sat Dec 16 11:47:14 GMT 2023 , Edited by admin on Sat Dec 16 11:47:14 GMT 2023
|
PRIMARY | |||
|
9955534
Created by
admin on Sat Dec 16 11:47:14 GMT 2023 , Edited by admin on Sat Dec 16 11:47:14 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
TARGET -> INHIBITOR |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
Class: Antithrombotic, Small molecule; Mechanism of Action: Thrombin inhibitor; Highest Development Phase: Phase I Blood coagulation disorder; Most Recent Event: 13 Apr 2016 - This programme is still active.
|
